 Connection
Michael Szarek to Hypoglycemic Agents
This is a "connection" page, showing publications Michael Szarek has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.111 |
|
|
|
-
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024 08; 12(8):545-557.
Score: 0.029
-
Aggarwal R, Bhatt DL, Szarek M, Leiter LA, Cannon CP, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PG. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr; 26(4):1093-1095.
Score: 0.029
-
Cherney DZI, Bhatt DL, Szarek M, Sun F, Girard M, Davies MJ, Pitt B, Steg PG. Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2023 11; 25(11):3410-3414.
Score: 0.027
-
Verma S, Bhatt DL, Dhingra NK, Steg PG, Szarek M, Davies M, Metra M, Lund LH, Pitt B. Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure. J Am Coll Cardiol. 2023 04 18; 81(15):1546-1549.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|